Dryvax Dilution-Prev Vacc Adults

National Institute of Allergy and Infectious Diseases (NIAID)90 enrolled

Overview

A double-blind, randomized, dose-response study of four dilutions of Dryvax in previously vaccinated adults in order to assess the clinical success rates, humoral responses, and virus-specific actifity of cytotoxi T cells and interferon-y producing T cells

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Smallpox

Interventions

DryvaxBIOLOGICAL

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * For cohort E (never vaccinated): Aged 18-31; Never been vaccinated for smallpox. * If female, not pregnant or lactating. * Promise to use an effective method of birth control for 7 months after vaccination. * Negative result on a test for HIV, AIDS, Hepatitis B and C. * Acceptable as blood donors. * For cohorts A, B, C, D (previously vaccinated): Aged 32 to 60 years; known history of smallpox vaccination with a typical vaccinia scar; no smallpox vaccination after 1971. * Healthy adults (aged 18-60). Exclusion Criteria: * Eczema or history of eczema, or other chronic skin disorder. * Pregnancy or lactation. * History of immunodeficiency, liver disease, severe kidney impairment, malignancy, HIV, Hepatitis B, or Hepatitis C. * Household contact with persons who are under 12 months of age, pregnant or lactating, or have any of the specified diseases.

Locations (1)

Saint Louis University Health Sciences Center

St Louis, Missouri, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.